YBX1 and non-small cell lung carcinoma: These findings are in agreement with elevated YB-1 levels, detected by an antibody generated to the same C-terminal peptide sequence, previously reported in breast cancer [22], [24], non-small cell lung cancer [13] and prostate [12].